Sitagliptin hydrochloride - Generic Drug Details

What are the generic sources for sitagliptin hydrochloride and what is the scope of freedom to operate?

Sitagliptin hydrochloride is the generic ingredient in one branded drug marketed by Azurity and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sitagliptin hydrochloride has five patent family members in four countries.

One supplier is listed for this compound.

Summary for sitagliptin hydrochloride

International Patents:	5
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	468
Patent Applications:	45
DailyMed Link:	sitagliptin hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for sitagliptin hydrochloride

Dosage:

SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for sitagliptin hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chong Kun Dang Pharmaceutical	PHASE4
Second Affiliated Hospital, School of Medicine, Zhejiang University	PHASE1
Case Comprehensive Cancer Center	PHASE2

See all sitagliptin hydrochloride clinical trials

Pharmacology for sitagliptin hydrochloride

Drug Class	Dipeptidyl Peptidase 4 Inhibitor
Mechanism of Action	Dipeptidyl Peptidase 4 Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for sitagliptin hydrochloride

A10BH	Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for sitagliptin hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	BRYNOVIN	sitagliptin hydrochloride	SOLUTION;ORAL	219122-001	Jan 16, 2025		RX	Yes	Yes			Y
Azurity	BRYNOVIN	sitagliptin hydrochloride	SOLUTION;ORAL	219122-001	Jan 16, 2025		RX	Yes	Yes			Y

International Patents for sitagliptin hydrochloride

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3811930
European Patent Office	4048230
Spain	2961549
Poland	4048230
World Intellectual Property Organization (WIPO)	2021078964

Supplementary Protection Certificates for sitagliptin hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1412357	DO 77; 5006-2008	Slovakia		PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
0896538	07C0035	France		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE IN FRANCE: EU/1/07/383/001 DU 20070321; REGISTRATION NO/DATE AT EEC: EU/1/07/383/001-018 DU 20070321
1412357	42/2007	Austria		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001-018 (MITTEILUNG) 20070323
1084705	CR 2014 00063	Denmark		PRODUCT NAME: SITAGLIPTIN OG FARMACEUTISK SALTE DERAF, HERUNDER SITAGLIPTIN PHOSPHAT MONOHYDRAT; REG. NO/DATE: EU/1/07/383/001-024 AND EU/1/07/382/001-024 20070323
1412357	106 4-2007	Slovakia		PRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: EU/1/07/383/001 - EU/1/07/383/018 20070321
1412357	SPC/GB08/040	United Kingdom		PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
1412357	C200700039	Spain		PRODUCT NAME: SITAGLIPTINA; NATIONAL AUTHORISATION NUMBER: EU/1/07/383/001-018; DATE OF AUTHORISATION: 20070321; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/383/001-018; DATE OF FIRST AUTHORISATION IN EEA: 20070321

Market Dynamics and Financial Trajectory for Sitagliptin Hydrochloride

Last updated: February 13, 2026

Overview: Sitagliptin hydrochloride is a dipeptidyl peptidase-4 (DPP-4) inhibitor prescribed primarily for type 2 diabetes management. It is marketed under brand names such as Januvia (Merck) and Januet (India). Since FDA approval in October 2006, it has become a significant component of the oral antidiabetic market.

Market Size and Growth Drivers: As of 2022, the global antidiabetic drug market was valued at approximately USD 66 billion, projected to reach USD 100 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6%. Sitagliptin remains a leading DPP-4 inhibitor with a market share around 20% in 2022, reflecting sales close to USD 13 billion globally.

Key growth drivers include:

• Rising prevalence of type 2 diabetes, projected to reach 700 million cases worldwide by 2045.
• Growing adoption of oral antidiabetic medications due to patient preference over injectable options.
• Expanding approval for combination therapies involving sitagliptin.
• Increased focus on cost-effective management strategies.

Market Dynamics: Multiple factors influence sitagliptin’s market trajectory:

1. Patent Status and Generic Competition:

   • The initial patent protection for Januvia expired in the US in 2017, leading to a surge in generic versions from companies such as Cipla, Sun Pharma, and others. Generics resulted in a dramatic reduction in efficacy-based pricing, dropping USD 15-25 per month per patient from USD 150-200.
   • Merck maintains exclusivity in some markets via patents on specific formulations and combination products, but generic erosion in big markets diminishes revenue potential.

2. Pricing Trends:

   • US retail prices have declined sharply post-generic entry, pressure that persists globally.
   • In emerging markets, branded sitagliptin retains higher pricing due to slower generic adoption.
   • Governments and payers increasingly demand price concessions; in the US, Medicaid and Medicare negotiated rebates lowering net sales.

3. Competitive Landscape:

   • Other DPP-4 inhibitors such as saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina) chip away at market share.
   • Novel antidiabetic classes like SGLT2 inhibitors (empagliflozin, canagliflozin) and GLP-1 receptor agonists (semaglutide, dulaglutide) challenge sitagliptin’s dominance, especially for patients requiring weight loss benefits or cardiovascular risk reduction.

4. Regulatory and Clinical Developments:

   • FDA warnings about rare cases of pancreatic cancer and joint pain have influenced prescribing patterns.
   • Ongoing studies assess cardiovascular and renal benefits versus competing therapies, influencing market access.

5. Forecast and Innovation:

   • Merck and other manufacturers are developing fixed-dose combinations (FDCs) with metformin, SGLT2 inhibitors, and GLP-1 drugs to retain customer base.
   • Limited pipeline of Next-Generation DPP-4 inhibitors that outperform sitagliptin economically or clinically constrains long-term sales growth.

Financial Trajectory: Initial peak sales of Januvia peaked at approximately USD 6.6 billion in 2012. Post-generic entry, sales declined to USD 4.9 billion in 2017. Recent figures indicate stabilization at USD 3.5-4 billion, primarily driven by market share in emerging economies and fixed-dose combinations.

Forecasts for the next five years suggest:

• Continued decline in brand-name sales due to generics, with sales projected down 20% to 30%.
• Growth in revenue from combination therapies, particularly in markets with delayed generic penetration.
• Innovation in formulation and delivery may stabilize or slightly increase sales in certain regions.

Key Risks and Opportunities:

• Risks: Patent litigation, regulatory restrictions, adverse clinical trial outcomes, and the move toward personalized medicine diminishing broad oral drug reliance.
• Opportunities: Expansion into new markets, development of innovative combination products, and positioning as part of multi-drug regimens for comprehensive diabetes care.

Summary Table:

Aspect	Data / Trend
Market Size (2022)	USD 13 billion (sitagliptin global sales)
CAGR (2022–2030)	6%
Major Competitors	Saxagliptin, linagliptin, alogliptin
Patent Expiry (US)	2017
Post-generic sales impact	20-30% decline post-2017
Emerging Markets	Higher retention of brand prices, slower generic uptake

Citations:

1. "Global Diabetes Drugs Market," MarketsandMarkets, 2022.
2. "Sitagliptin Market Analysis," IQVIA, 2022.
3. "Patent and Regulatory Data," FDA, 2022.
4. "Generic Entry Impact," IMS Health, 2019.
5. "Diabetes Prevalence Estimates," International Diabetes Federation, 2022.

---

Key Takeaways:

• Generic competition has sharply reduced sitagliptin’s revenue since patent expiration in 2017.
• The global market is shifting toward combination therapies and newer drug classes with cardio-renal benefits.
• Despite revenue erosions, growth persists in emerging markets where brand competition remains limited.
• Innovation in drug delivery and formulation remains critical for maintaining market share.
• The evolving competitive landscape necessitates continuous strategic adjustments by pharmaceutical companies.

FAQs:

1. How has patent expiry affected sitagliptin’s sales?
   Patent expiry in 2017 led to a significant sales decline of up to 30% due to generic competition.

2. What are the main competitors to sitagliptin?
   Saxagliptin, linagliptin, and alogliptin, along with emerging SGLT2 and GLP-1 class drugs, compete for market share.

3. Are there any new formulations or combinations in development?
   Yes, fixed-dose combinations with metformin, SGLT2 inhibitors, and GLP-1 drugs are expanding available options.

4. Which markets remain most profitable for sitagliptin?
   Emerging economies with slower generic uptake and higher branded medication retention.

5. What are future growth prospects for sitagliptin?
   Limited, as revenue declines due to generics but potentially stable through combination therapy sales and new markets.

---

[1] MarketsandMarkets, "Global Diabetes Drugs Market," 2022.
[2] IQVIA, "Sitagliptin Market Analysis," 2022.
[3] FDA, "Patent Data," 2022.
[4] IMS Health, "Impact of Generics," 2019.
[5] International Diabetes Federation, "Diabetes Atlas," 2022.